Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Septerna, Inc.NASDAQ: SEPN
Other Non-current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Other non-current liabilities falls 44.4% from a year ago
Other non-current liabilities stood at $67.13M at the end of Q3 FY2026, down 44.4% from a year earlier and down 16.7% from the prior quarter. Over 3 fiscal years it compounded at +12.3% a year.
Context
- Other non-current liabilities amounted to 10.8% of total assets at the end of Q3 FY2026, down 9.0 pp from a year earlier.
- Other non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -44.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 105.92M USD
- Year-over-year change
- +320860.6%
- 3-year CAGR
- +12.3%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 105.92M | +320860.6% |
| FY2024 | 2024-12-31 | 33K | -100.0% |
| FY2023 | 2023-12-31 | 149.76M | +100.3% |
| FY2022 | 2022-12-31 | 74.78M | — |
Other Non-current Liabilities vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 other non-current liabilities of $67.13M is the highest of the 7 companies compared; the peer median is $265.5K.
- Its year-over-year change of -44.4% is the 3rd highest of 5, against a peer median of -31.4%.
- Other non-current liabilities amounts to 10.8% of total assets for SEPN, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | Sep 2026 | $67.13M | -44.4% | +12.3% | 10.8% |
| Mar 2026 | $18.37M | — | — | 39.6% | |
| Jun 2026 | $1.27M | +299.1% | -85.2% | 0.1% | |
| Mar 2026 | $388K | -61.4% | — | 0.1% | |
| Mar 2026 | $143K | -1.4% | -39.4% | 0.1% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $135K | — | — | 0.0% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $0 | -100.0% | -97.1% | 0.0% |
| Peer median (excluding SEPN) | $265.5K | -31.4% | -85.2% | 0.1% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.